342 related articles for article (PubMed ID: 29210107)
1. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
[TBL] [Abstract][Full Text] [Related]
2. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
Kim E; Howes OD; Park JW; Kim SN; Shin SA; Kim BH; Turkheimer FE; Lee YS; Kwon JS
Psychol Med; 2016 Jan; 46(2):357-66. PubMed ID: 26423910
[TBL] [Abstract][Full Text] [Related]
3. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
Wolmarans de W; Brand L; Stein DJ; Harvey BH
Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
[TBL] [Abstract][Full Text] [Related]
4. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder.
Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Wenzel T; Zettinig G; Hornik K; Pirker W; Thau K
Neuropsychopharmacology; 2008 Dec; 33(13):3126-34. PubMed ID: 18354388
[TBL] [Abstract][Full Text] [Related]
5. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.
Stengler-Wenzke K; Müller U; Barthel H; Angermeyer MC; Sabri O; Hesse S
Neuropsychobiology; 2006; 53(1):40-5. PubMed ID: 16397403
[TBL] [Abstract][Full Text] [Related]
6. Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [
Kim E; Howes OD; Kim BH; Chon MW; Seo S; Turkheimer FE; Lee JS; Lee YS; Kwon JS
Clin Pharmacokinet; 2017 Apr; 56(4):371-381. PubMed ID: 27557550
[TBL] [Abstract][Full Text] [Related]
7. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study.
Matsumoto R; Ichise M; Ito H; Ando T; Takahashi H; Ikoma Y; Kosaka J; Arakawa R; Fujimura Y; Ota M; Takano A; Fukui K; Nakayama K; Suhara T
Neuroimage; 2010 Jan; 49(1):121-6. PubMed ID: 19660554
[TBL] [Abstract][Full Text] [Related]
8. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder.
Hesse S; Stengler K; Regenthal R; Patt M; Becker GA; Franke A; Knüpfer H; Meyer PM; Luthardt J; Jahn I; Lobsien D; Heinke W; Brust P; Hegerl U; Sabri O
Int J Neuropsychopharmacol; 2011 Jun; 14(5):606-17. PubMed ID: 21232166
[TBL] [Abstract][Full Text] [Related]
9. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD).
Pogarell O; Poepperl G; Mulert C; Hamann C; Sadowsky N; Riedel M; Moeller HJ; Hegerl U; Tatsch K
Eur Neuropsychopharmacol; 2005 Oct; 15(5):521-4. PubMed ID: 16139170
[TBL] [Abstract][Full Text] [Related]
10. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.
Zitterl W; Stompe T; Aigner M; Zitterl-Eglseer K; Ritter K; Zettinig G; Hornik K; Asenbaum S; Pirker W; Thau K
Biol Psychiatry; 2009 Dec; 66(12):1115-22. PubMed ID: 19717141
[TBL] [Abstract][Full Text] [Related]
11. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas.
Lanzenberger R; Kranz GS; Haeusler D; Akimova E; Savli M; Hahn A; Mitterhauser M; Spindelegger C; Philippe C; Fink M; Wadsak W; Karanikas G; Kasper S
Neuroimage; 2012 Nov; 63(2):874-81. PubMed ID: 22828162
[TBL] [Abstract][Full Text] [Related]
12. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.
Reimold M; Smolka MN; Zimmer A; Batra A; Knobel A; Solbach C; Mundt A; Smoltczyk HU; Goldman D; Mann K; Reischl G; Machulla HJ; Bares R; Heinz A
J Neural Transm (Vienna); 2007; 114(12):1603-9. PubMed ID: 17713719
[TBL] [Abstract][Full Text] [Related]
13. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652.
Simpson HB; Lombardo I; Slifstein M; Huang HY; Hwang DR; Abi-Dargham A; Liebowitz MR; Laruelle M
Biol Psychiatry; 2003 Dec; 54(12):1414-21. PubMed ID: 14675806
[TBL] [Abstract][Full Text] [Related]
14. Brain neurochemistry in unmedicated obsessive-compulsive disorder patients and effects of 12-week escitalopram treatment:
Parmar A; Sharan P; Khandelwal SK; Agarwal K; Sharma U; Jagannathan NR
Psychiatry Clin Neurosci; 2019 Jul; 73(7):386-393. PubMed ID: 30973183
[TBL] [Abstract][Full Text] [Related]
15. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
[TBL] [Abstract][Full Text] [Related]
17. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder.
Jang JH; Kwon JS; Jang DP; Moon WJ; Lee JM; Ha TH; Chung EC; Kim IY; Kim SI
Am J Psychiatry; 2006 Jul; 163(7):1202-7. PubMed ID: 16816225
[TBL] [Abstract][Full Text] [Related]
18. [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
Ginovart N; Wilson AA; Meyer JH; Hussey D; Houle S
Synapse; 2003 Feb; 47(2):123-33. PubMed ID: 12454950
[TBL] [Abstract][Full Text] [Related]
19. Serotonin Synthesis and Reuptake in Social Anxiety Disorder: A Positron Emission Tomography Study.
Frick A; Åhs F; Engman J; Jonasson M; Alaie I; Björkstrand J; Frans Ö; Faria V; Linnman C; Appel L; Wahlstedt K; Lubberink M; Fredrikson M; Furmark T
JAMA Psychiatry; 2015 Aug; 72(8):794-802. PubMed ID: 26083190
[TBL] [Abstract][Full Text] [Related]
20. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
Stein DJ; Andersen EW; Overo KF
Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
